Pacira BioSciences, Inc. Overview
Pro stress-test →Pacira BioSciences delivers innovative, non-opioid pain therapies with three commercial-stage non-opioid treatments and a novel gene therapy asset advancing to treat large prevalent diseases like osteoarthritis. The company focuses on transforming patient outcomes through locally-administered pain management solutions in a market driven by the opioid crisis and shift toward safer alternatives.
Strategic Profile
Pro stress-test →Pacira projects 77-79% gross margins for 2026, driven by success of its flagship product EXPAREL, which benefits from increased reimbursement, wider commercial use, and intellectual property protection extending into the 2040s. The company is expanding market reach through strategic partnerships and enhanced intellectual property protection.
Competitive Landscape
Pro stress-test →Competitors include Grifols, Noven Pharmaceuticals, Tris Pharma, Pfizer Pakistan, and Pfizer Manufacturing Austria. Pacira holds a leading position in non-opioid local pain management with strong IP protection, facing competition from larger pharma players and alternative pain management technologies.
Industry Context
Pacira BioSciences, Inc. operates in Biopharmaceutical - Specialty Pain Management / Non-Opioid Therapeutics.
Key facts
Founded: 2006 · Headquarters: Tampa, Florida, US · Revenue: $726.4M · Market cap: $962M